Cartesian Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cartesian Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $373.00K, a 338.82% increase year-over-year.
- Cartesian Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $304.00K, a 66.12% increase year-over-year.
- Cartesian Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $5.00K, a 91.07% decline year-over-year.
- Cartesian Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $85.00K, a 29.17% decline year-over-year.
- Cartesian Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $298.00K, a 74.72% decline from fiscal 2024.
- Cartesian Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.18M.
- Cartesian Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $156.00K, a 79.95% decline from fiscal 2021.
- Cartesian Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $778.00K, a 303.11% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $373.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $304.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $298.00K 10-K · filed 2026-03-09 | |
| 2025-09-30 | $5.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $85.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $183.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.18M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $56.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $120.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $154.00K 10-Q · filed 2025-11-06 | |
| 2022-12-31 | $156.00K 10-K · filed 2024-03-07 | |
| 2022-09-30 | $135.00K 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $21.00K 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $778.00K 10-K · filed 2024-03-07 | |
| 2021-09-30 | $5.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $425.00K 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $244.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $193.00K 10-K · filed 2023-03-02 | |
| 2020-06-30 | $98.00K 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $3.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $150.00K 10-K · filed 2022-03-10 | |
| 2019-09-30 | $5.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $145.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $501.00K 10-K · filed 2021-03-12 | |
| 2018-09-30 | $109.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $311.00K 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $705.00K 10-K · filed 2020-03-12 |
| 2017-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $721.00K derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $604.00K derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $436.00K 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $149.00K 10-K · filed 2019-03-15 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | |
| 2015-12-31 | $86.00K 10-K · filed 2018-03-15 | |
| 2014-12-31 | $68.00K 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |